Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | CTSE | P14091 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318440 | 0.88 | CCR5 (0.62) | CCR5OPRL1SLC6A9SLC6A5OPRM1 | |
| SCHEMBL17140870 | 0.88 | CCR5 (0.62) | CCR5OPRL1SLC6A9OPRM1OPRK1 | |
| SCHEMBL318858 | 0.88 | CCR5 (0.75) | CCR5OPRL1SLC6A9OPRM1OPRK1 | |
| SCHEMBL17141010 | 0.87 | CCR5 (0.59) | CCR5SLC6A9OPRM1OPRK1HTR2C | |
| SCHEMBL17149522 | 0.85 | CCR5 (0.57) | CCR5SLC6A9OPRM1OPRK1HTR2C | |
| SCHEMBL17141181 | 0.84 | ALDH1A1 (0.59) | CCR5OPRL1SLC6A9OPRM1ALDH1A1 | |
| SCHEMBL17140779 | 0.82 | ALDH1A1 (0.48) | CCR5ALDH1A1GPR119CTSDCTSE | |
| SCHEMBL18940736 | 0.81 | CCR5 (0.61) | CCR5OPRL1SLC6A9SLC6A5OPRM1 | |
| SCHEMBL17140776 | 0.80 | NPC1L1 (0.47) | CCR5OPRL1OPRM1ALDH1A1OPRK1 | |
| SCHEMBL17149491 | 0.79 | ALDH1A1 (0.47) | CCR5ALDH1A1GPR119CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
| US-5610142-A | Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids | SCIOS INC. (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRL1 264/4885SLC6A9 1923/4885 |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | CCR5 409/4885OPRL1 28/4885SLC6A9 1499/4885 |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | CCR5 36/4885OPRL1 264/4885SLC6A9 1927/4885 |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, CXCR3, SLC10A1 | CCR5 36/4885OPRL1 264/4885SLC6A9 1927/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRL1 264/4885SLC6A9 1923/4885 |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | CCR5 37/4885OPRL1 264/4885SLC6A9 1923/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | CCR5 409/4885OPRL1 28/4885SLC6A9 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.